A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo, in Adult Subjects With Chronic Idiopathic Constipation
Phase of Trial: Phase III
Latest Information Update: 27 May 2017
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 30 Mar 2017 Status changed from planning to recruiting.
- 14 Mar 2017 New trial record
- 08 Mar 2017 This trial is expected to begin in 1Q 2017, according to a Sucampo Pharmaceuticals media release.